How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
Immunovant, Inc., healthcare (market value $6.0 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.
Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.
What do the best‑ranked analysts on IMVT say now? See it in Exent Gems →
Over the 5 years to Oct 30, 2026, Immunovant, Inc. (IMVT) returned +262.8% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 186.9 percentage points, or +29.4% a year against +12.0%.
| Period | IMVT | S&P 500 | IMVT per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | +18.2% | +12.0% | +18.2% | +12.0% | Beat |
| 3 years | −11.7% | +87.4% | −4.1% | +23.3% | Lagged |
| 5 years | +262.8% | +75.9% | +29.4% | +12.0% | Beat |
| Period | 1 year | 3 years | 5 years |
|---|---|---|---|
| IMVT | +18.2% | −11.7% | +262.8% |
| S&P 500 | +12.0% | +87.4% | +75.9% |
| IMVT per year | +18.2% | −4.1% | +29.4% |
| S&P 500 per year | +12.0% | +23.3% | +12.0% |
| Result | Beat | Lagged | Beat |
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
In the 12 months to 30 days ago, 17 analysts published 116 ratings on IMVT. Their latest calls were 76% Buy, 24% Hold and 0% Sell. 10 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.
The consensus 12‑month price target was $40.00 (range $40.00–$40.00), +20.6% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?
| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
|---|---|---|---|
| ??? | ??? | 5.0★ | 27.3% |
| Sam Slutsky | LifeSci Capital | 5.0★ | 30.1% |
| ??? | ??? | 5.0★ | 43.4% |
| ??? | ??? | 4.9★ | 36.9% |
| ??? | ??? | 4.9★ | 41.7% |
Other analysts covering IMVT: Eddie Hickman · Danielle Brill
Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on IMVT are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.
The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.
IMVT beat the S&P 500 in 3 of the 6 full calendar years shown.
| Year | IMVT | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | +14.8% | +11.7% | +3.1% |
| 2025 | +2.6% | +17.7% | −15.1% |
| 2024 | −41.2% | +24.9% | −66.1% |
| 2023 | +137.4% | +26.2% | +111.2% |
| 2022 | +108.3% | −18.2% | +126.5% |
| 2021 | −81.6% | +28.7% | −110.3% |
| 2020 | +191.1% | +18.3% | +172.8% |
Over 5 years, IMVT had a Sharpe ratio of 0.58 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 72.5% and its beta 0.96: it tended to move about 1.0× as much as the market.
| Metric | IMVT | S&P 500 |
|---|---|---|
| Annual return | +29.4% | +12.0% |
| Volatility (annualized) | 72.5% | 15.5% |
| Sharpe ratio | 0.58 | 0.58 |
| Sortino ratio | 1.55 | 0.91 |
| Max drawdown (month-end) | −65.1% | −23.9% |
| Beta to the S&P 500 | 0.96 | 1.00 |
IMVT’s deepest fall in the crises below was −61.5% in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.
| Crisis | IMVT | S&P 500 | Loss on $100,000 |
|---|---|---|---|
| COVID crash (Feb–Mar 2020) | −50.9% | −34.1% | −$50,940 |
| 2022 inflation bear market | −61.5% | −25.4% | −$61,460 |
| 2025 tariff selloff | −37.4% | −19.0% | −$37,420 |
| Window | IMVT max drawdown |
|---|---|
| Last 1 year | −21.0% |
| Last 3 years | −69.9% |
| Last 5 years | −70.4% |
| Last 10 years | −93.6% |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, IMVT’s correlation with the S&P 500 was 0.20, with the Nasdaq‑100 0.16, with long Treasuries (TLT) −0.06 and with gold (GLD) −0.10.
Adding a 5% IMVT position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.8%.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| VZ | −0.24 | CAT | 0.41 |
| WM | −0.20 | JPM | 0.34 |
| CME | −0.15 | ISRG | 0.34 |
| META | −0.15 | GILD | 0.34 |
| SO | −0.11 | VRT | 0.34 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
No named analyst changed a rating or price target on IMVT in the 5 weeks to Oct 20, 2026 (calls are shown 30 days after publication). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.
Of the 276 analyst price targets on IMVT set from 2019 until a year ago, 36.2% were reached within 12 months (data to Oct 20, 2026), 32.4 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 81 days. The median target sat 61.0% above the share price on the day it was set.
Where analysts said IMVT would be by now: a year ago, 6 analysts had a price target on IMVT, and the median of their latest targets was $39.50. On Oct 20, 2026 IMVT closed at $28.61, 27.6% below it.
| After | Calls | Move on the call | 3 months vs S&P 500 |
|---|---|---|---|
| Upgrades of IMVT | 4 | +27.1% | +21.9% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |
| Downgrades of IMVT | 7 | −26.0% | −39.5% |
| Downgrades, all stocks | 10,700 | −3.0% | −1.6% |
The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on IMVT through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?
IMVT beat the consensus earnings‑per‑share estimate in 5 of its last 12 quarterly reports, through the one on Aug 6, 2026, and the revenue estimate in 0 of 1. From the close before each report to the close after it, the stock moved 6.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 6 of the 12 reports. In 2 of the 5 beats the stock still fell.
| Report | EPS vs estimate | Revenue vs estimate | Stock move |
|---|---|---|---|
| Aug 6, 2026 | −$0.75 vs −$0.63 | 0.0% | +1.7% |
| May 20, 2026 | −$0.73 vs −$0.59 | — | +29.8% |
| Feb 6, 2026 | −$0.61 vs −$0.72 | — | +14.3% |
| Nov 10, 2025 | −$0.73 vs −$0.72 | — | −2.0% |
| Aug 11, 2025 | −$0.60 vs −$0.69 | — | −1.6% |
| May 29, 2025 | −$0.64 vs −$0.71 | — | +5.3% |
| Feb 6, 2025 | −$0.76 vs −$0.73 | — | −9.3% |
| Nov 7, 2024 | −$0.74 vs −$0.61 | — | −2.5% |
Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings
In the 12 months to Oct 20, 2026, IMVT insiders made no open‑market purchases and 52 sales worth $16.3 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Dec 12, 2025.
After the 36 insider purchases of $10,000 or more since 2012, IMVT beat the S&P 500 by an average of 254.6 percentage points over the next 12 months; 74% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.
| Date | Insider | Role | Value |
|---|---|---|---|
| Dec 12, 2025 | Roivant Sciences Ltd. | Director, 10 percent owner | $350.0 million |
| Jan 13, 2025 | Roivant Sciences Ltd. | Director, 10 percent owner | $336.9 million |
| Oct 2, 2023 | Roivant Sciences Ltd. | Director, 10 percent owner | $58.0 million |
| Oct 6, 2022 | Roivant Sciences Ltd. | Director | $2.5 million |
| Sep 30, 2022 | Pande Atul | Director | $84,000 |
The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?
As of the Sep 30, 2026 settlement date, 20.53% of IMVT’s float was sold short: 17.4 million shares, or 9.6 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 20.05%. The median across the 997 US stocks Exent tracks was 4.77%, so IMVT is more heavily shorted than most.
From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks
At the end of Q2 2026 (Jun 30, 2026), 240 institutions reported holding IMVT in 13F filings, up 13 from the quarter before and up from 181 a year earlier. Their reported holdings add up to 54.0% of IMVT’s shares. In the quarter 113 institutions added to their positions and 82 cut them.
Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling
IMVT’s diluted share count rose 107.9% over the five fiscal years to fiscal 2026 and rose 20.4% in fiscal 2026 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.
Stock‑based compensation was $55.7 million in fiscal 2026. IMVT did not buy back shares in fiscal 2026.
Weighted‑average diluted shares from IMVT’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained
In Exent’s Oct 20, 2026 snapshot, IMVT’s Altman Z‑score was 25.07, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 3 out of 9; 94% of scored stocks reach 3 or more.
The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?
As of Oct 20, 2026, 17 of the 304 ETFs Exent tracks held IMVT. Its largest weight is in XBI (State Street SPDR S&P Biotech ETF), at 0.60% of the fund.
| ETF | Fund | Weight of IMVT |
|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 0.60% |
| IWO | iShares Russell 2000 Growth ETF | 0.17% |
| VTWO | Vanguard Russell 2000 Index Fund | 0.10% |
| VBK | Vanguard Small-Cap Growth Index Fund ETF Shares | 0.09% |
| IWM | iShares Russell 2000 ETF | 0.08% |
| SCHA | Schwab U.S. Small-Cap ETF | 0.06% |
| SCHM | Schwab U.S. Mid-Cap ETF | 0.05% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.05% |
Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?
Exent matches every holding to the index with the most similar risk. For IMVT that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
| Ticker | Name | 5‑year return | Volatility (5y) |
|---|---|---|---|
| LLY | Eli Lilly and Company | +482.3% | 32.6% |
| JNJ | Johnson & Johnson | +92.9% | 16.8% |
| ABBV | AbbVie Inc. | +207.1% | 23.5% |
| RYTM | Rhythm Pharmaceuticals, Inc. | +704.3% | 74.0% |
| KOD | Kodiak Sciences Inc. | +323.5% | 99.3% |
| TFX | Teleflex Incorporated | −59.3% | 35.1% |
| LGND | Ligand Pharmaceuticals Incorporated | +254.5% | 44.4% |
| DOCS | Doximity, Inc. | −52.8% | 63.3% |
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
Wall Street’s average IMVT price target is 20.6% above the latest share price. See what the best‑ranked analysts on IMVT say now in Exent Gems.
Yes. IMVT returned +262.8% (+29.4% a year) over the 5 years to Oct 30, 2026, versus +75.9% (+12.0% a year) for the S&P 500, including dividends.
No. As of Oct 20, 2026, IMVT (Immunovant, Inc.) is not one of the 503 stocks in the S&P 500.
No. As of Oct 20, 2026, IMVT (Immunovant, Inc.) is not one of the 101 stocks in the Nasdaq-100.
IMVT fell −50.9% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.
IMVT fell −61.5% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.
Over the 5 years to Oct 30, 2026, IMVT’s Sharpe ratio was 0.58 and its Sortino ratio 1.55, versus 0.58 and 0.91 for the S&P 500.
IMVT’s 5‑year annualized volatility was 67.4%, higher than the S&P 500’s 17.0%, with a beta of 0.96.
Among large US stocks, the lowest correlations with IMVT over the last 60 months were VZ (−0.24), WM (−0.20), CME (−0.15). Its correlation with long Treasuries (TLT) was −0.06 and with gold (GLD) −0.10.
IMVT beat the consensus earnings-per-share estimate in 5 of its last 12 quarterly reports through Aug 6, 2026, and the revenue estimate in 0 of 1. The stock moved 6.7% on average, up or down, from the close before each report to the close after it.
As of the Sep 30, 2026 settlement date, 20.53% of IMVT’s float was sold short (17.4 million shares, 9.6 days to cover), according to FINRA short-interest reports. A year earlier it was 20.05%.
Yes. IMVT’s diluted share count rose 107.9% over the five fiscal years to fiscal 2026 and rose 20.4% in the latest year.
Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on IMVT are, their latest calls and the stocks where several of them agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.